LiVeritas Biosciences
Harnessing Molecular Integrity for Early Informed Decision Making
LiVeritas Biosciences
Harnessing Molecular Integrity for Early Informed Decision Making
Harnessing Molecular Integrity for Early Informed Decision Making
Harnessing Molecular Integrity for Early Informed Decision Making
We value truth, integrity, respect, and excellence in doing more for others. We believe that patients deserve therapeutic treatments developed under stringent data integrity and quality standards.
Truth. Chemistry. Liber. Veritas. LiVeritas.
We simplify the complexity of drug development analytical operations and mass spectrometry by delivering high quality data at a lower cost and faster turn-around-time. By harnessing the power of mass spectrometry and digital transformation, we are offering accurate, precise, and timely solutions to drug candidates quality testing that use a fraction of resources.
Our team has designed and optimized analytical test packages that are effective in rapidly advancing drug candidates in the development pipeline and aid in process development.
We offer partner-centric software solutions that streamlines mass spectrometry digitization, analytical operations, and drug product knowledge management.
Our team is composed of industry experts with milestone focused biotech startup backgrounds grounded in biopharma core competencies.
Guaranteed team of experts and proprietary know-how to guide every step of the process
Guaranteed efficiency of streamlined processes and careful selection of IND-enabling tests
Guaranteed effectiveness of solutions and information delivery for astute decision making at the speed of the industry
There is a growing need for high-quality analytical analysis using mass spectrometry to characterize biopharmaceuticals to enable the delivery of the best medicines to patients. Small amounts of variants and modifications in biological products need to be identified and monitored to ensure quality, safety, and efficacy. The team at LiVeritas have the knowledge and experience to deliver characterization data for every stage of drug development with rapid turnaround times to meet accelerated filing deadlines.
Amy Hilderbrand, PhD
Former Molecular Assessment Analytical Lead, Genentech PAC
Current Affiliation : Frontier Medicines
Previous Affiliations : Thermo Fisher Scientific, Roche, GSK, Antheia, Fitbit
Lieza provided a level of mass spectrometry expertise that allowed us to more effectively develop antibody-drug conjugates (ADCs) from research to manufacturing to nonclinical and clinical development. She was pivotal in characterization/optimization of both small and large molecules, including ADCs.
Tae Han, PhD
Former Director, Clinical Pharmacology & Pharmacokinetics, Stemcentrx
Current Affiliation : Co-Founder & COO, Profound Therapeutics
Previous Affiliations : Merck, Seattle Genetics, Amphivena Therapeutics
Copyright © 2020 LiVeritas Biosciences, Inc. - All Rights Reserved.